Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
शेयरों में रैंक #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
शेयर मूल्य
$58.70
अंतिम समन्वयन: 2024-01-23
मार्केट कैप
$2.98B
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Mirati Therapeutics, Inc. (MRTX)

श्रेणी

Mirati Therapeutics, Inc. (MRTX) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $58.94 (2024-01-01 को)

दिन का सबसे निम्न समापन मूल्य: $8.67 (2013-07-01 को)
Mirati Therapeutics, Inc. के स्टॉक मूल्य का इतिहास 2013 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
वर्ष प्रदर्शन
2024 2.02%
2023 12.06%
2022 -63.56%
2021 -39.15%
2020 103.16%
2019 189.49%
2018 132.29%
2017 218.41%
2016 -84.08%
2015 98.82%
2014 1.02%
2013 0.00%
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
कंपनी स्टॉक मूल्य परिवर्तन 1व% देश
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.50 -12.74%
AU
$764.47 7.08%
CH